Clinical Trial Update: Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated suvorexant for therapeutic exposure benefits in posttraumatic stress disorder, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttraumatic Stress Disorder

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Howard University | Conditions: Posttraumatic Stress Disorder | Phase 4 | Status: COMPLETED | Results posted: 2023-06-02